Email this   Print this

Outpatient Management of Depression 12 - References

References

1. Adler LA, Angrist BM, Paroxetine and akathisia. Biol Psychiatry. 1995;37:336-337
2. Alderman CP, Seshadri P, Ben-Tovim DI, Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother. 1996;30:1232-1234
3. American Academy of Child and Adolescent Psychiatry, Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1998;37(suppl 10):275-455
4. American Psychiatric Association, Practice guidelines for major depressive disorder in adults. Am J Psychiatry. 1993;150(suppl 4):1-26
5. Amsterdam JD, Garcia-Espana F, Goodman D, Hooper M, Hornig-Rohan M, Breast enlargement during chronic antidepressant therapy. J Affect Disord. 1997;46:151-156
6. Andreasen NC, Rice J, Endicott J, Coryell W, Grove WM, Reich T, Familial rates of affective disorder. A report from the National Institute of Mental Health Collaborative Study [published erratum appears in Arch Gen Psychiatry. 1988;45:776]. Arch Gen Psychiatry. 1987;44:461-469
7. Anonymous, Drugs for psychiatric disorders. Med Lett Drugs Ther. 1994;36:89-96
8. Arana GW, Baldessarini RJ, Ornsteen M, The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry. 1985;42: 1193-1204
9. Armitage R, Trivedi M, Rush AJ, Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacology. 1995;12:159-165
10. Armitage R, Rush AJ, Trivedi M, Cain J, Roffwarg HP, The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology. 1994;10:123-127
11. Armstrong SC, Schweitzer SM, Delirium associated with paroxetine and benztropine combination. Am J Psychiatry. 1997;154:581-582. Letter
12. Aronson TA, Shukla S, Hoff A, Cook B, Proposed delusional depression subtypes: Preliminary evidence from a retrospective study of phenomenology and treatment course. J Affect Disord. 1988;14:69-74
13. Ayd FJ, Paroxetine, a new selective serotonin reuptake inhibitor. Int Drug Ther Newsletter. 1993;28:5-12
14. Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS, Akathisia: A review and case report following paroxetine treatment. Compr Psychiatry. 1996;37:122-124
15. Baldwin D, Fineberg N, Montgomery S, Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol. 1991;6:51-58
16. Balon R, Antidepressants in the treatment of premature ejaculation. J Sex Marital Ther. 1996;22:85-96
17. Barker EL, Blakely RD, Norepinephrine and serotonin transporters: Molecular targets of antidepressant drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994;321-334
18. Barr LC, Goodman WK, Price LH, Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry. 1994;151:289. Letter
19. Bayer AJ, Roberts NA, Allen EA, et al, The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scan. 1989;80(suppl 350):85-86
20. Beasley CM, Masica DN, Heiligenstein JH, et al, Possible monoamine oxidate inhibitor-serotonin uptake inhibitor interaction: Fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol. 1993;13:312-320
21. Beck AT, Brown G, Berchick RJ, Stewart BL, Steer RA, Relationship between hopelessness and ultimate suicide: A replication with psychiatric outpatients. Am J Psychiatry. 1990;147:190-195
22. Beedle D, Krasuski J, Janicak PG, Advances in somatic therapies: Electroconvulsive therapy, repetitive transcranial magnetic stimulation and bright light therapy. In: Janicak PG, Davis JM, Preskorn SH, Ayd FJ, eds. Principles and Practice of Psychopharmacotherapy. 2nd ed. Baltimore, Md: L
23. Bergeron R, Blier P, Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry. 1994;151:1084-1086
24. Bertschy G, Baumann P, Eap CB, Baettig D, Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit. 1994;16:42-45
25. Bhatara VS, Bandettini FC, Possible interaction between sertraline and tranylcypromine. Clin Pharmacol. 1993;12: 222-225
26. Blayac JP, Hillaire-Buys D, Peyriére H, Pharmacovigilance of new antidepressants: Evaluation of neuropsychobehavioral disorders [in French] Therapie. 1997;52:117-122
27. Blier P, Bergeron R, The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry. 1998;59(suppl 5):16-23, 24-25
28. Bloch M, Stager SV, Braun AR, Rubinow DR, Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet. 1995;346:57. Letter
29. Blume CD, Dear doctor letter regarding use of eldepryl. Tampa, Fla: Somerset Pharmaceuticals; 1994, Nov 14
30. Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ, Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58:137-145
31. Bolden-Watson C, Richelson E, Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52:1023-1029
32. Brannan SK, Talley BJ, Bowden CL, Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol. 1994;14:144-145. Letter
33. Bremner JD, Wingard P, Walshe TA, Safety of mirtazapine in overdose. J Clin Psychiatry. 1998;59:233-235
34. Broadhead WE, Blazer DG, George LK, Tse CK, Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990;264:2524-2528
35. Brown GW, Harris TO, Social Origins of Depression:A Study of Psychiatric Disorder in Women. London, UK: Tamstock Publications; 1978
36. Brown WA, Dornseif BE, Wernicke JF, Placebo response in depression: A search for predictors. Psychiatry Res. 1988;26: 259-264
37. Brown WA, Harrison W, Are patients who are intolerant to one SSRI intolerant to another? Psychopharmcol Bull. 1992;28:253-256
38. Bryois C, Rubin C, Zbinden JD, Baumann P, Withdrawal syndrome caused by selective serotonin reuptake inhibitors: apropos of a case [in French] Schweiz Rundsch Med Prax. 1998;87:345-348
39. Bunney WE Jr, Goodwin FK, Murphy DL, House KM, Gordon EK, The "switch process" in manic-depressive illness. II. Relationship to catecholamines, REM sleep, and drugs. Arch Gen Psychiatry. 1972;27:304-309
40. Burke MJ, Silkey B, Preskorn SH, Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry. 1994;55(suppl A):42-52, 53-54, 98-100
41. Burrows GD, Maguire KP, Norman TR, Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry. 1998;59 (suppl 14):4-7
42. Caccia S, Ballabio M, Samanin R, Zanini MG, Garattini S, (--)-m-Chlorophenylpiperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J Pharm Pharmacol. 1981;33:477-478
43. Carpenter LL, McDougle CJ, Epperson CN, Price LH, A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Saf. 1996;15:116-134
44. Celexa (citalopram hydrobromide) [package insert]. St. Louis, Mo: Forest Pharmaceuticals, Inc; 1998
45. Choo V, Paroxetine and extrapyramidal reactions. Lancet. 1993;341:624. Letter
46. Chouinard G, Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 1992;7(suppl 2):37-41
47. Claghorn JL, Feighner JP, A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J Clin Psychopharmacol. 1993;13(suppl 2):23S-27S
48. Clerc GE, Ruimy P, Verdeau-Pallés J, A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol. 1994;9:139-143
49. Committee on Safety of Drugs, Curr Prob Pharmacovigilance. 1993;19:1
50. Cooper TA, Valcour VG, Gibbons RB, O’Brien-Falls K, Spontaneous ecchymoses due to paroxetine administration. Am J Med. 1998;104:197-198
51. Coplan JD, Gorman JM, Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry. 1993;150:837
52. Costa e Silva J, Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1998;59:352-357
53. Coupland NJ, Bell CJ, Potokar JP, Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16:356-362
54. Cusack B, Nelson A, Richelson E, Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology. 1994;114:559-565
55. Danish University Antidepressant Group, Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 1986;90:131-138
56. Danish University Antidepressant Group, Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affective Disorder. 1990;18:289-299
57. Davidson J, Seizures and bupropion: a review. J Clin Psychiatry. 1989;50:256-261
58. de Boer T, Ruigt G, Berendsen H, The alpha2-selective adrenoceptor antagonist Org 3770 (mirtazapine remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol. 1995;10:107S-118S
59. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM, Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988;27:399-408
60. Dechant KL, Clissold SP, Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991;41:225-253
61. Depression Guideline Panel, Clinical Practice Guideline. Number 5. Depression in Primary Care, Vol. 1: Detection and Diagnosis; and Vol 2: Treatment of Major Depression. Rockville, Md: US Dept. of Health and Human Services, Public Health Service, AHCPR Publication No. 93-0551; April
62. Doogan DP, Caillard V, Sertraline in the prevention of depression. Br J Psychiatry. 1992;160:217-222
63. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994
64. Dunner DL, Gershon ES, Goodwin FK, Heritable factors in the severity of affective illness. Biol Psychiatry. 1976;11:31-42
65. Effexor XR (venlafaxine hydrochloride) Extended-Release Capsules. In: Physicians’ Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company, Inc; 1999:3298-3302
66. Eldepryl (selegiline hydrochloride). In: Physicians’ Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company, Inc; 1999:3128-3131
67. Eric LT, A prospective double-blind comparative multicentre study of paroxetine and placebo in preventing recurrent major depression episodes. Biol Psychiatry. 1991; 29(suppl 11):2545
68. Esposito S, Prange AJ Jr, Golden RN, The thyroid axis and mood disorders: overview and future prospects. Psychopharmacol Bull. 1997;33:205-217
69. Evans D, Antidepressant adverse effects and antidepressants in the medically ill. Am Soc Clin Psychopharm Progress Notes. 1995;6:22-25
70. Evans ME, Kortas KJ, Potential interaction between isoniazid and selective serotonin-reuptake inhibitors. Am J Health Syst Pharm. 1995;52:2135-2136. Letter
71. Fawcett J, Marcus RN, Anton SF, O’Brien K, Schwiderski U, Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry. 1995;56(suppl 6):37-42
72. Fawcett J, Scheftner W, Clark D, Hedeker D, Gibbons R, Coryell W, Clinical predictors of suicide in patients with major affective disorders: a controlled prospective study. Am J Psychiatry. 1987;144:35-40
73. Feighner JP, Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry. 1995;56:574-579
74. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ, Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry. 1990;51:222-225
75. Flockhart DA, Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol. 1996;16:101-103
76. Frank E, Kupfer DJ, Perel JM, et al, Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47:1093-1099
77. Frazer A, Antidepressants. J Clin Psychiatry. 1997;58(suppl 6):9-25
78. Frost L, Lal S, Shock-like sensations after discontinuance of selective serotonin reuptake inhibitors. Am J Psychiatry. 1995;152:810. Letter
79. Garnier R, Azoyan P, Chataigner D, Taboulet P, Dellattre D, Efthymiou ML, Acute fluvoxamine poisoning. J Intern Med Res. 1993;21:197-208
80. Gershon ES, Berrettini W, Numberger J Jr, Goldin LR, Genetics of affective illness. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:481-491
81. Giammusso B, Morgia G, Spampinato A, Motta M, Paroxetine in the treatment of premature ejaculation [in Italian] Arch Ital Urol Androl. 1997;69:11-13
82. Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ, A comparison of nefazodone and fluoxetine on mood and on objective, subjective, clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. [published erratum appears in J Clin Psychiatry. 1997;58:275]. J Clin Psychiatry
83. Glennon RA, Dukat M, Serotonin receptor subtypes. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994: 415-430
84. Gonzalez FJ, Skoda RC, Kimura S, et al, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988;331:442-446
85. Goodwin DW, Guze SB, Psychiatric Diagnosis. 4th ed. New York, NY: Oxford University Press; 1989:22
86. Goodwin DW, Preskorn SH, DSM-III and pharmacotherapy. In: Turner S, Hersen M, eds. Adult Psychopathology: A Behavioral Perspective. New York, NY: John Wiley & Sons; 1982:453-465
87. Graber MA, Hoehns TB, Perry PJ, Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother. 1994;28:732-735
88. Gram LF, Debruyne D, Caillard V, et al, Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol. 1989;27:272-275
89. Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G, The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiatr Scand. 1989;80(suppl 350):95-98
90. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC, Efficacy and tolerability of serotonin transport inhibitors in obessive-compulsive disorder. A metaanalysis. Arch Gen Psychiatry. 1995;52:53-60
91. Grimsley SR, Jann MW, Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm. 1992;11:930-957
92. Harris MG, Benfield P. Fluoxetine, A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. Drugs Aging. 1995;6:64-84
93. Harvey AT, Preskorn SH, Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol. 1996;16:273-285
94. Harvey AT, Preskorn SH, Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol. 1996;16:345-355
95. Heinemann F, Assion HJ, Hermes G, Ehrlich M, Paroxetine-induced neuroleptic malignant syndrome [in German] Nervenarzt. 1997;68:664-666
96. Helzer JE, Burnam A, McEvoy LT, Alcohol abuse and dependence. In: Robins LN, Regier DA, Freedman DX, eds. Psychiatric Disorders in America: The Epidemiological Catchment Area Study. New York, NY: Free Press; 1991:81-115
97. Heninger GR, Charney DS, Sternberg DE, Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refactory depression. Arch Gen Psychiatry. 1983;40:1335-1342
98. Hirschfeld RM, Keller MB, Panico S, et al, The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277: 333-340
99. Holliday SM, Plosker GL, Paroxetine: a review of its pharmacology, therapeutic use in depression, and therapeutic potential in diabetic neuropathy. Drugs Aging. 1993;3:278-299
100. Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A, Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol. 1992;6(suppl 4):43-51
101. Hyttel J, Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry. 1993;47 (suppl 30):5-12
102. Isaksen PM, The effect of an antidepressant agent on premature ejaculation [in Norwegian] Tidsskr Nor Laegeforen. 1995;115:1616-1617
103. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr, Principles and Practice of Psychopharmacotherapy. 2nd ed. Baltimore, Md: Lippincott, Williams & Wilkins; 1997
104. Jermain DM, Hughes PL, Follender AB, Potential fluoxetine-selegiline interaction. Ann Pharmacother. 1992;26:1300. Letter
105. Joffe RT, Levitt AJ, Sokolov ST, Young LT, Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57:114-115
106. Joffe RT, Singer W, Levitt AJ, et al, A placebo-controlled comparison of lithium and triidothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387-393
107. Kahn RS, Asnis GM, Wetzler S, van Praag HM, Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology. 1988;96:360-364
108. Katona CL, Hunter BN, Bray J, A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998;13:100-108
109. Kaul S, Shukla UA, Barbhaiya RH, Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol. 1995;35:830-839
110. Kaye CM, Haddock RE, Langley PF, et al, A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand. 1989;80(supp 350):60-75
111. Kelland MD, Freeman AS, Chiodo LA, Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther. 1990;253:803-811
112. Keller MB, Kocsis JH, Thase ME, et al, Maintenance phase efficacy of sertraline for chronic depression. A randomized controlled trial. JAMA. 1998;280:1665-1672
113. Kerr JS, Fairweather DB, Mahendran R, Hindmarch I, The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. Int Clin Psychopharmacol. 1992;7:101-108
114. Kessler LG, Cleary PD, Burke JD Jr, Psychiatric disorders in primary care. Results of a followup study. Arch Gen Psychiatry. 1985;42:583-587
115. Ketter TA, Flockhart DA, Post RM, et al, The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995;15:387-398
116. Kety SS, Genetic factors in suicide. In: Roy A, ed. Suicide. Baltimore, Md: Williams & Wilkins; 1986:41-45
117. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA, Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol. 1994;14: 206-207. Letter
118. Kiloh LG, Andrews G, Neilson M, The longterm outcome of depressive illness. Br J Psychiatry. 1988;153:752-757
119. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST, Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol. 1992;32:716-724
120. Kline SS, Mauro LS, Scala-Barnett DM, Zick D, Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm. 1989;8:510-514
121. Knesper DJ, Riba MB, Schwenk TL, Primary Care Psychiatry. Philadelphia, Pa: WB Saunders Co; 1997
122. Kupfer DJ, Longterm treatment of depression. J Clin Psychiatry. 1991;52(suppl 5):28-34
123. Kupfer DJ, Frank E, Perel JM, et al, Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1992;49:769-773
124. Kupfer DJ, Frank E, Perel JM, The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry.1989;46:771-775
125. Landry P, Roy L, Withdrawal hypomania associated with paroxetine. J Clin Psychopharmacol. 1997;17:60-61
126. Lazowick AL, Levin GM, Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother. 1995;29:1284-1285
127. Lebegue B, Mania precipitated by fluoxetine. Am J Psychiatry. 1987;144:1620. Letter
128. Lejoyeux M, Ades J, Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997;58(suppl 7):11-16
129. Leonard BE, The comparative pharmacology of new antidepressants. [published erratum appears in J Clin Psychiatry. 1993;54:491]. J Clin Psychiatry. 1993;54(suppl):3-15
130. Lewis J, Braganza J, Williams T, Psychomotor retardation and semistuporous state with paroxetine. Br Med J. 1993;306: 1169
131. Lin KM, Poland RE, Ethnicity, culture and psychopharmacology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994:1907-1918
132. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N, Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303-1307
133. Louie AK, Lannon RA, Ajari LJ, Withdrawal reaction after sertraline discontinuation. Am J Psychiatry. 1994;151:450-451. Letter
134. Ludovico GM, Corvasce A, Pagliarulo G, Cirillo-Marucco E, Marano A, Pagliarulo A, Paroxetine in the treatment of premature ejaculation. Br J Urol. 1996;77:881-882
135. Luvox (fluvoxamine maleate). Compendium of Pharmaceuticals and Specialities. 33rd ed. Ottawa, Ontario, Canada: Canadian Pharmaceutical Association; 1998;922-924
136. Malek-Ahmadi P, Allen SA, Paroxetine-molindone interaction. J Clin Psychiatry. 1995;56:82-83. Letter
137. Marshall RD, Schneier FR, Fallon BA, et al, An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol. 1998;18:10-18
138. Mathew NT, Tietjen GE, Lucker C, Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia. 1996;16: 323-327
139. Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH, Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos. 1994;22:304-311
140. McClelland GR, Raptopoulos P, Psychomotor effects of paroxetine and amitriptyline, alone and in combination with alcohol. Br J Clin Pharmacol. 1985;19:578P. Abstract
141. McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM Jr, Gross LS, The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry. 1990;51(suppl):60-69
142. Merikangas KR, Weissman MM, Pauls DL, Genetic factors in the sex ratio of major depression. Psychol Med. 1985;15: 63-69
143. Miller F, Friedman R, Tanenbaum J, Griffin A, Disseminated intravascular coagulation and acute myoglobinuric renal failure: a consequence of the serotonergic syndrome. J Clin Psychopharmacol. 1991;11:277-279. Letter
144. Mills KC, Serotonin syndrome. Am Fam Physician. 1995;52:1475-1482
145. Modell JG, Katholi CR, Modell JD, DePalma RL, Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther. 1997;61:476-487
146. Montejo AI, Llorca G, Izquierdo JA, et al, Sexual dysfunction secondary to SSRIs. A comparative analysis in 308 patients [in Spanish] Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1996;24:311-321
147. Montejo-Gonzales AL, Llorca G, Izquierdo JA, et al, SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997; 23:176-194
148. Montgomery SA, Dufour H, Brion S, et al, The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry. 1988;153(suppl 3):69-76
149. Moreno FA, Geleberg AJ, Bachar K, Delgado PL, Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 1997;58:437-439
150. Narayan M, Anderson G, Cellar J, Mallison RT, Price LH, Nelson JC, Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol. 1998;18:67-71
151. Nelson JC, Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997;58(suppl 6):26-31
152. Nelson JC, Mazure CM, Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry. 1986;143:363-366
153. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI, A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303-307
154. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E, Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993;342;1419. Letter
155. Nierenberg AA, Cole JO, Glass L, Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry. 1992;53:83-85
156. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J, Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14:19-23
157. Nierenberg AA, White K, What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull. 1990;26:429-460
158. Nierenberg DW, Semprebon M, The central nervous system serotonin syndrome. Clin Pharmacol Ther. 1993;53:84-88
159. Oswald I, Adam K, Effects of paroxetine on human sleep. Br J Clin Pharmacol. 1986;22:97-99
160. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F, Psychotic (delusional) depression: a metaanalysis of physical treatments. J Affect Disord. 1992;24:17-24
161. Paxil (paroxetine hydrochloride). In: Physicians’ Desk Reference. 53rd ed. Montevale, NJ: Medical Economics Company, Inc; 1999:3078-3083
162. Peet M, Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164:549-550
163. Pigott TA, OCD: where the serotonin selectivity story begins. J Clin Psychiatry. 1996;57(suppl 6):11-20
164. Pincus HA, Tanielian TL, Marcus SC, et al, Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA. 1998;279:526-531
165. Pollock BG, Mulsant BH, Nebes R, et al, Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry. 1998;155:1110-1112
166. Potter WZ, Rudorfer MV, Manji H, The pharmacologic treatment of depression. N Engl J Med. 1991;325:633-642
167. Preskorn SH, Dose-effect and concentration-effect relationships with new antidepressants. In: Gram LF, Balant LP, Meltzer SG, Dahl SG, eds. Clinical Pharmacology in Psychiatry: Strategies in Psychotropic Drug Development. Berlin: Heidelberg; 1993:174-189
168. Preskorn SH, A message from Titanic. J Prac Psych Behav Hlth. 1998;4:236-242
169. Preskorn SH, Antidepressant drug selection: criteria and options. J Clin Psychiatry. 1994;55(suppl A):6-22, 23-24, 98-100
170. Preskorn SH, Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Caddo, Okla: Professional Communications, Inc; 1996
171. Preskorn SH, Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline and venlafaxine. J Clin Psychiatry. 1995;56(suppl 6):12-21
172. Preskorn SH, Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. J Psychopharmacol. 1998;12:S89-S97
173. Preskorn SH, Do you feel lucky? J Prac Psycho Behav Hlth. 1998;4:37-40
174. Preskorn SH, I don’t see ’em. J Prac Psych Behav Hlth. 1997; 3:302-307
175. Preskorn SH, Introduction: pharmacokinetics of psychotropic agents: why and how they are relevant to treatment. J Clin Psychiatry. 1993;54(suppl 9):3-7
176. Preskorn SH, Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. J Clin Psychiatry. 1993;54(suppl 9):14-34
177. Preskorn SH, Recent dose-effect studies regarding antidepressants. In: Balant LP, Benitez J, Dahl SG, Gram LF, Pinder RM, Potter WZ, eds. European Cooperation in the Field of Scientific and Technical Research. Belguim: European Commission; 1998:45-61
178. Preskorn SH, Selection of an antidepressant: mirtazapine. J Clin Psychiatry. 1997;58(suppl 6):3-8
179. Preskorn SH, Serotonin receptor subtypes and their implications for psychiatric disorders. In: Hagerman RJ, KcKenzie P, edsl.1992 International Fragile X Conference Proceddings. Dillon, Colo: Spectra Publishing Co; 1992: 179-194
180. Preskorn SH, Should bupropion dosage be adjusted based upon therapeutic drug monitoring? Psychopharmacol Bull. 1991;27:637-643
181. Preskorn SH, Should rational drug development in psychiatry target more than one mechanism of action in a single molecule?. Intl Rev Psychiatry. 1995;7:17-28
182. Preskorn SH, The appearance of knowledge. J Prac Psych Behav Hlth. 1997;3:233-238
183. Preskorn SH, The future and psychopharmacology: potentials and needs. Psychiatr Ann. 1990;20(suppl 11):625-633
184. Preskorn SH, The revolution in psychiatry. Phi Kappa Phi. Winter 1993:22-25
185. Preskorn SH, Tricyclic antidepressants: the whys and hows of therapeutic drug monitoring. J Clin Psychiatry. 1989;50 (suppl):34-42, 43-46
186. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S, Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14:90-98
187. Preskorn SH, Baker B, Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA. 1997;277:1682. Letter
188. Preskorn SH, Bupp S, Weller E, Weller R, Plasma levels of imipramine and metabolites in 68 hospitalized children. J Am Acad Child Adoesc Psychiatry. 1989;28:373-375
189. Preskorn SH, Burke M, Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry. 1992;53(suppl 9):5-18
190. Preskorn SH, Fast GA, Beyond signs and symptoms: the case against a mixed anxiety and depression category. J Clin Psychiatry. 1993;54(suppl):24-32
191. Preskorn SH, Fast GA, Therapeutic drug monitoring for antidepressants: Efficacy, safety and cost effectiveness. J Clin Psychiatry. 1991;52(suppl 6):23-33
192. Preskorn SH, Harvey A, Stanga C, Drug interactions and their role in patient care. Curr Rev Mood Anxiety Disord. 1997;1: 203-214
193. Preskorn SH, Jerkovich GS, Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors and the role of therapeutic drug monitoring. J Clin Psychopharmacol. 1990;10:88-95
194. Preskorn SH, Kent TA, Mechanisms and interventions in tricyclic antidepressant overdoses. In: Stancer HC, Garfinkel PE, Rakoff VM, eds. Guidelines for the Use of Psychotropic Drugs: A Clinical Handbook. Spectrum Publications, Inc; 1984:63-75
195. Preskorn SH, Lacey R, Polypharmacy: when is it rational? J Prac Psych Behav Hlth. 1995;1:92-98
196. Preskorn SH, Othmer SC, Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy. 1984;4:20-34
197. Preskorn SH, Shad MU, Alderman J, Lane R, Fluoxetine: Age and dose dependent pharmacokinetics and CYP 2C19 inhibition. Am Soc Clin Pharmacol Ther. 1998;63:166. Abstract
198. Price JS, Waller PC, Wood SM, MacKay AV, A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 1996;42:757-763
199. Prien RF, Kupfer DJ, Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry. 1986;143:18-23
200. Prozac (fluoxetine hydrochloride). In: Physicians’ Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company, Inc; 1999:924-928
201. Quitkin FM, Harrison W, Liebowitz M, et al, Defining the boundaries of atypical depression. J Clin Psychiatry. 1984; 045:19-21
202. Redux (dexfenfluramine hydrochloride) [package insert]. Philadelphia, Pa: Wyeth-Ayerst Laboratories; 1996
203. Remeron (mirtazapine). In: Physicians’ Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company, Inc: 1999:2147-2149
204. Reynolds RD, Serotonin syndrome: what family physicians need to know. Am Fam Physician. 1995;52:1263, 1266, 1271. Editorial
205. Robertson MM, Trimble MR, Depressive illness in patients with epilepsy: a review. Epilepsia. 1983;24(suppl 2):S109-S116
206. Robins E, Completed suicide. In: Roy A, ed. Suicide. Baltimore, Md: Williams & Wilkins; 1986:123-133
207. Robins E, The Final Months: A Study of the Lives of 134 Persons Who Committed Suicide. New York, NY: Oxford University Press; 1981
208. Robinson DS, Roberts DL, Smith JM, et al, The safety profile of nefazodone. J Clin Psychiatry. 1996;57(suppl 2):31-38
209. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB, Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44: 77-87
210. Rosenbaum JF, Zajecka J, Clinical management of antidepressant discontinuation. J Clin Psychiatry. 1997;58(suppl 7):37-40
211. Roth A, Akyol S, Nelson JC, Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. J Clin Psychiatry. 1994;55:492-495
212. Rouillon F, Gorwood P, The use of lithium to augment antidepressant medication. J Clin Psychiatry. 1998;59(suppl 5):32-39
213. Rowland DL, Myers L, Culver A, Davidson JM, Bupropion and sexual function: a placebo-controlled prospective study on diabetic men with erectile dysfunction. J Clin Psychopharmacol. 1997;17:350-357
214. Rush AJ, Armitage R, Gillin JC, et al, Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry. 1998;44:3-14
215. Rush AJ, Kupfer DJ, Strategies and tactics in the treatment of depression. In: Gabbard GO, ed. Treatments of Psychiatric Disorders. 2nd ed. Washington, DC: American Psychiatric Press, Inc; 1996
216. Sackeim HA, Devanand DP, Nobler MS, Electroconvulsive therapy. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994:1123-1142
217. Saletu B, Frey R, Krupka M, Anderer P, Grünberger J, See WR, Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep. 1991;14:439-447
218. Sanders-Bush E, Mayer SE, 5-Hydroxytryptamine (serotonin) receptor agonists and antagonists. In: Gilman AG, consulting ed; Hardman JG, Limbird LE, eds-in-chief; Molinoff PB, Ruddon RW, eds. Goodman and Gilman’s: The Pharmacological Basis of Therapeutics. 9th ed. New York, NY:
219. Schatzberg AF, Haddad P, Kaplan EM, et al, Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry. 1997;58(suppl 7):23-27
220. Schwartz JC, Arrang JM, Garbarg M, Traiffort E, Histamine. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994;397-406
221. Series HG, Drug treatment of depression in medically ill patients. J Psychosom Res. 1992;36:1-16
222. Settle EC Jr, Settle GP, A case of mania associated with fluoxetine. Am J Psychiatry. 1984;141:280-281
223. Shad MU, Preskorn SH, Antidepressants. In: Levy R, Thummel KE, Trager W, Hansten PD, Eichelbaum M, eds. Metabolic Drug Interactions - Drugs as Inhibitors of Metabolic Enzymes Treatment of CNS Diseases. Philadelphia, Pa: Lippincott, Williams & Wilkins. In press
224. Shad MU, Preskorn SH, A drug-drug interaction in reverse: Possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. Journal of Clinical Psychopharmacology 19(5):471-472, 1999
225. Shad MU, Preskorn SH, A possible bupropion and imipramine interaction. J Clin Psychopharmacol. 1997;17:118-119. Letter
226. Sharpley AL, Williamson DJ, Attenburrow ME, Pearson G, Sargent P, Cowen PJ, The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology. 1996;126:50-54
227. Spielberg SP, N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm. 1996;24:509-519
228. Sporer KA, The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 1995;13:94-104
229. Stahl MM, Lindquist M, Pettersson M, et al, Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol. 1997;53: 163-169
230. Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J, Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep. 1995;18:470-477
231. Stein G, Bernadt M, Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry. 1993;162:634-640
232. Sternbach H, Danger of MAOI therapy after fluoxetine withdrawal. Lancet. 1988;2:850-851. Letter
233. Sternbach H, The serotonin syndrome. Am J Psychiatry. 1991;148:705-713
234. Stuppaeck CH, Geretsegger C, Whitworth AB, et al, A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol. 1994;14:241-246
235. Sussman N, Anxiolytic antidepressant augmentation. J Clin Psychiatry. 1998;59(suppl 5):42-48
236. Tallman JF, Dahl SG, New drug design in psychopharmacology: the impact of molecular biology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994:1861-1874
237. Taylor DP, Carter RB, Eison AS, et al, Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56(suppl 6):3-11
238. Tecott LH, Sun LM, Akana SF, et al, Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 1995;374:542-546
239. Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA, Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998;339:875-882
240. Thase ME, Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59:502-508
241. Thase ME, The undertreatment of patients with depression. Depressive Disorders: Index and Reviews. 1996;1:4, 16-17
242. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG, Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry. 1997;58:16-21
243. Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ, Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry. 1992;53:5-11
244. Thase ME, Howland RH, Friedman ES, Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry. 1998;59(suppl 5):5-12, 13-15
245. Thase ME, Rush AJ, Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1994: 1081-1097
246. Thase ME, Rush AJ, When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23-29
247. The APA Task Force on Laboratory Tests in Psychiatry, The dexamethasone suppression test: an overview of its current status in psychiatry. Am J Psychiatry. 1987;144:1253-1262
248. Thomas DR, Nelson DR, Johnson AM, Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology. 1987;93: 193-200
249. Tielens JA, Vitamin C for paroxetine- and fluvoxamine-associated bleeding. Am J Psychiatry. 1997;154:883-884. Letter
250. Treatment of panic disorder. NIH Consensus Statement Online. 1991; September 25-27; 9(2):1-24
251. Tucker P, Adamson P, Miranda R Jr, et al, Paroxetine increases heart rate variability in panic disorder. J Clin Psychopharmacol. 1997;17:370-376
252. Turner SM, Jacob RG, Beidel DC, Griffin S, A second case of mania associated with fluoxetine. Am J Psychiatry. 1985;142: 274-275. Letter
253. Vogel GW, Vogel F, McAbee RS, Thurmond AJ, Improvement of depression by REM sleep deprivation. New findings and a theory. Arch Gen Psychiatry. 1980;37:247-253
254. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI, Cytochromes in psychopharmacology. J Clin Psychopharmacol. 1994;14:1-4. Editorial
255. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI, Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet. 1995;29(suppl 1):33-44
256. Waldinger MD, Hengeveld MW, Zwinderman AH, Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. Br J Urol. 1997;79:592-595
257. Waldinger MD, Hengeveld MW, Zwinderman AH, Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 1994:151:1377-1379
258. Weilburg JB, Rosenbaum JF, Meltzer-Brody S, Shushtari J, Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry. 1991;3:209-213.
259. Weissman MM, Affective disorders. In: Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiological Catchment Area Study. New York, NY: Free Press; 1991:53-80
260. Weissman MM, Klerman GL, Sex differences in the epidemiology of depression. Arch Gen Psychiatry. 1977;34:98-111
261. Weissman MM, Leaf PJ, Holzer CE III, Myers JK, Tischler GL, The epidemiology of depression. An update on sex differences in rats. J Affect Disord. 1984;7:179-188
262. Weissman MM, Wickramaratne P, Merikangas KR, et al, Onset of major depression in early adulthood. Increased familial loading and specificity. Arch Gen Psychiatry. 1984;41:1136-1143
263. Weller EB, Weller RA, Fristad MA, Preskorn SH, The dexamethasone suppression test in hospitalized prepubertal depressed children. Am J Psychiatry. 1984;141:290-291
264. Wells KB, Stewart A, Hays RD, et al, The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914-919
265. Wender PH, Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry. 1998;59(suppl 7):76-79
266. Wernicke JF, The side effect profile and safety of fluoxetine. J Clin Psychiatry. 1985;46:59-67
267. Wheatley DP, van Moffaert M, Timmerman L, Kremer CM, Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry. 1998;59:306-312
268. Winokur G, Unipolar depression: is it divisible into autonomous subtypes? Arch Gen Psychiatry. 1979;36:47-52
269. Winokur G, Tsuang MT, Crowe RR, The Iowa 500: affective disorder in relatives of manic and depressed patients. Am J Psychiatry. 1982;139:209-212
270. Wolkenstein P, Cremniter D, Roujeau JC, Toxic epidermal necrolysis after paroxetine treatment. Eur Psychiatry. 1995;10:162. Letter
271. Yocca FD, Hyslop DK, Taylor DP, Nefazodone: a potential broad spectrum antidepressant. Trans Am Soc Neurochem. 1985;16:115
272. Zajecka J, Tracy KA, Mitchell S, Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry. 1997;58:291-297
273. Zoloft (sertraline hydrochloride). In: Physicians’ Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company, Inc; 1999:2443-2448
274. Zyban (bupropion hydrochloride). In: Physicians’ Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company, Inc; 1999:1277-1282
275. Zygmont M, Prigerson HG, Houck PR, et al, A post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. J Clin Psychiatry. 1998;59:241-245